WO1995017378A1 - Compose pouvant introduire au moins une molecule dans une cellule - Google Patents

Compose pouvant introduire au moins une molecule dans une cellule Download PDF

Info

Publication number
WO1995017378A1
WO1995017378A1 PCT/BE1994/000096 BE9400096W WO9517378A1 WO 1995017378 A1 WO1995017378 A1 WO 1995017378A1 BE 9400096 W BE9400096 W BE 9400096W WO 9517378 A1 WO9517378 A1 WO 9517378A1
Authority
WO
WIPO (PCT)
Prior art keywords
group
chosen
alkyl chains
compound
formula
Prior art date
Application number
PCT/BE1994/000096
Other languages
English (en)
Inventor
Jean-Marie Ruysschaert
Robert Fuks
Original Assignee
Universite Libre De Bruxelles
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universite Libre De Bruxelles filed Critical Universite Libre De Bruxelles
Priority to JP7517056A priority Critical patent/JPH09508099A/ja
Priority to DE69430321T priority patent/DE69430321T2/de
Priority to EP95902010A priority patent/EP0736002B9/fr
Priority to AU11039/95A priority patent/AU1103995A/en
Publication of WO1995017378A1 publication Critical patent/WO1995017378A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C257/00—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines
    • C07C257/04—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines without replacement of the other oxygen atom of the carboxyl group, e.g. imino-ethers
    • C07C257/06—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines without replacement of the other oxygen atom of the carboxyl group, e.g. imino-ethers having carbon atoms of imino-carboxyl groups bound to hydrogen atoms, to acyclic carbon atoms, or to carbon atoms of rings other than six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C257/00—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines
    • C07C257/10—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. amidines
    • C07C257/14—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. amidines having carbon atoms of amidino groups bound to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8201—Methods for introducing genetic material into plant cells, e.g. DNA, RNA, stable or transient incorporation, tissue culture methods adapted for transformation
    • C12N15/8206—Methods for introducing genetic material into plant cells, e.g. DNA, RNA, stable or transient incorporation, tissue culture methods adapted for transformation by physical or chemical, i.e. non-biological, means, e.g. electroporation, PEG mediated

Definitions

  • the invention relates to a compound capable of introducing at least one molecule into a cell.
  • the invention also relates to a positively charged vesicle whose membrane comprises this compound, to a vector containing at least one molecule combined with the vesicle according to the invention; to the cell, animal and/or plant transformed by said compound or said vector as well as to the pharmaceutical or cosmetic composition, comprising said vector and/or the cell transformed by said vector.
  • the invention also relates to the process for the synthesis of said compound and to the process for the production of said vector.
  • Another aspect of the invention relates to the use of the compound and/or vector for the introduction in vitro and/or in vivo of at least one molecule into a cell.
  • Transfection is a method which is widely used for introducing genetic material into cells, for studying the expression of genes, and for developing strategies for gene therapy.
  • Another axis of research relates to the development of new amphiphilic cationic vectors which have demonstrated their effectiveness and their ease of use for causing the genetic material to penetrate into cells in vitro (P.L. Feigner et al . , Proc. Natl. Acad. Sci., USA, 84, pp. 7413-7417 (1987)) .
  • DOTMA DOTMA from GIBCO BRL or the Transfection-reagent ®
  • Patent Application O91/15501 also describes a positively charged reagent consisting of a neutral phospholipid such as dioleoylphosphatidyl- ethanolamine and a cationic lipid such as stearylamine, a tertiary amine or a benzothorium salt for the transfec- tion of nucleic acids.
  • a neutral phospholipid such as dioleoylphosphatidyl- ethanolamine
  • a cationic lipid such as stearylamine, a tertiary amine or a benzothorium salt for the transfec- tion of nucleic acids.
  • Lipofectin ® (DOTMA) has the addi- tional disadvantage of not being capable of being added to a serum.
  • OR is the residue of an alcohol of formula ROH and R 2 is chosen from the group comprising a hydrogen atom, saturated alkyl chains, unsaturated alkyl chains and substituted alkyl chains; an intermediate compound which is necessary for the production of the compounds according to the invention.
  • the aim of the present invention is to produce a new compound and/or a new vector capable of introducing at least one molecule into a cell, without exhibiting the disadvantages of the prior state of the art .
  • the invention is also intended for producing a pharmaceutical or cosmetic composition comprising said vector and/or said cell transformed by said vector.
  • An additional aim of the present invention is intended for producing a vector which can be used in a serum.
  • the present invention relates to a compound of general formula:
  • - A is chosen from the group consisting of the radicals comprising a hydrophilic group or a CH 2 group and a hydrophobic group;
  • - n is a positive integer, preferably n>l;
  • R 2 , R 3 and R 4 are chosen ••1 from the group consisting of a hydrogen atom, saturated alkyl chains, unsaturated alkyl chains and substituted alkyl chains.
  • A represents a radical of formula - X - R 1 in which
  • R 1 is chosen from the group consisting of a hydrogen atom, saturated alkyl chains, unsaturated alkyl chains and substituted alkyl chains, and
  • - X represents a divalent atom or a divalent group of atoms chosen from the group consisting of
  • R 1 and R 3 or R 1 and R 4 are chosen from the group consisting of hydrocarbon chains con ⁇ taining 12 or more carbon atoms, preferably 12 to 18 carbon atoms.
  • the compound corresponds to the following formula:
  • the invention also relates to a positively charged vesicle having a membrane comprising a compound according to the invention as well as a vector consisting of said vesicle associated with at least one molecule chosen from the group consisting of nucleic acids such as plasmids, messenger RNAs , antisense RNAs, cDNAs, synthetic oligonucleotides and the like which are capable of genetically transforming a cell, antigens, polypep- tides or optionally glycosylated proteins and/or active therapeutic or cosmetic agents.
  • nucleic acids such as plasmids, messenger RNAs , antisense RNAs, cDNAs, synthetic oligonucleotides and the like which are capable of genetically transforming a cell, antigens, polypep- tides or optionally glycosylated proteins and/or active therapeutic or cosmetic agents.
  • Another aspect of the invention relates to a process for the introduction of at least one molecule chosen from the group consisting of nucleic acids, antigens, polypeptides or optionally glycosylated pro ⁇ teins and/or active therapeutic or cosmetic agents, into a cell, in which process said cell is brought into contact with said molecule and a compound and/or a vesicle according to the invention.
  • this introduction process can be achieved by bringing said cell into contact with a vector according to the inven- tion.
  • a cell is treated in vitro in order to produce plants or animals which are transgenic or in order to produce gene therapy, in particular for the treatment of cellular disorders such as cancer or infec ⁇ tions such as viral or bacterial infections or the like.
  • a cell is treated in vitro in order to produce recombinant microorganisms, plants and/or animals which are transgenic or in order to produce gene therapy.
  • the present invention also relates to the cell transformed by the vector according to the invention, the animal and/or plant transformed by the vector or said cell according to the invention, as well as a cosmetic or pharmaceutical composition such as a vaccine, comprising the vector according to the invention and/or the trans ⁇ formed cell according to the invention.
  • the invention also relates to a process for the production of the vector according to the invention in which at least one molecule chosen from the group con ⁇ sisting of nucleic acids, antigens, polypeptides and optionally glycosylated proteins and/or active therapeu- tic or cosmetic agents are reacted with a vesicle accord ⁇ ing to the invention.
  • Another aspect of the invention relates to the intermediate compound of formula:
  • OR is the residue of an alcohol of formula ROH
  • R 2 is chosen from the group comprising a hydrogen atom, saturated alkyl chains, unsaturated alkyl chains and substituted alkyl chains.
  • a final aspect of the invention relates to the use of the vector and/or the compound according to the invention for the introduction of one or more molecules into a cell in vitro as well as the use of the vector according to the invention for the introduction of one or more molecules into a cell in vivo.
  • the present invention is based on the unexpected fact that a compound of general formula:
  • - A is chosen from the group consisting of the radicals comprising a hydrophilic group or a CH 2 group and a hydrophobic group; - n is an integer, preferably > 1,
  • R 2 , R 3 and R 4 are chosen from the group consisting of a hydrogen atom, saturated alkyl chains, unsaturated alkyl chains and substituted alkyl chains, can form vesicles and combine with other molecules to form a vector capable of introducing said molecules into an animal or plant cell or a microorganism.
  • other molecules there is understood any molecular structure such as a nucleic acid, an antigen, a polypeptide or an optionally glycosylated protein or an active therapeutic or cosmetic agent, capable of modi ⁇ fying the state of said cell, in particular the physico- chemical state or the genome of said cell .
  • the suspension is cooled to -80°C and 46.8 g (10.8 mol) of 0 absolute ethanol (dried and distilled over magnesium) are added thereto, with stirring.
  • the temperature of the mixture is allowed to rise up to -20°C and then it is added to 800 ml of 1.5 M aqueous sodium hydroxide cooled to 0°C.
  • the mixture is then separated after settling has 5 taken place at room temperature.
  • the aqueous phase is extracted 3 times with 100 ml of dichloromethane.
  • the combined organic phases are dried over magnesium sulfate and then filtered. After addition of a spatula-tip quantity of hydroquinone, the solution is evaporated using a rotary evaporator, the bath should not exceed 30°C.
  • Alkylamine 5_ Acrylimidate 1_ Hexane and Yield Al 2 0 3 n 12; 18.5 g 7.75 g 50 ml; 200 g 15.47 g; 65%
  • n 16; 19.28 g 6.2 g 60 ml; 160 g 14.6 g; 62%
  • n 18; 21.5 g 6.2 g 80 ml; 160 g 15.69 g; 61%
  • a solution of diC 14 -amidine is prepared in ethanol (100 mg/ml) .
  • 30 ⁇ l (3 mg) of this solution are rapidly' injected, by means of a Hamilton syringe, into 3 ml of Tris/HCl buffer (0.01 M, pH 7.4) , heated to 30°C.
  • the solution is gently stirred by means of a magnetic bar.
  • the vesicles form immedia ⁇ tely.
  • Example I Formation of the vector vesicles-plasmid DNA
  • the cells are cultured in 6-well culture dishes until they are 80-90% confluent.
  • the suspension containing the complex (diC 14 - amidine-DNA or diC 14 -amidine/PE-DNA) is gently mixed with 2 ml of culture medium.
  • the culture medium used for the transfection operation is identical to the usual culture medium for the cells to be transformed.
  • the optional presence of serum in the medium has no inhibitory action on the transfection process and can even prove necessary for many cell lines (especially in suspension) .
  • the mixture thus formed constitutes the "transfection medium” .
  • the cells (about 10 s ) are washed with the culture medium and the transfection medium is added.
  • the medium is incubated for the desired period. This period may depend on the cell line to be transfected but an incubation time of 2-3 h is generally used. After incuba ⁇ tion, the transfection medium is replaced with fresh medium; 6 hours later, the cells can be transferred into 100 mm culture dishes.
  • the suspension containing the complex (diC 14 -ami- dine-DNA or diC 14 -amidine/PE-DNA) is gently mixed with 10 ml of medium.
  • the mixture thus formed constitutes the "transfection medium”.
  • Aliquots of 10 6 cells are centri- fuged and the pellets are resuspended in the transfection medium.
  • the cell suspensions are distributed into 100 mm culture dishes. The suspensions are incubated for the desired period; after incubation, the cells are centri- fuged and resuspended in 10 ml of fresh medium and then cultured normally.
  • CHO Choinese Hamster Ovary cells are cultured in F12 medium supplemented with 1% glutamine and 1% penicil ⁇ lin/streptomycin and containing 10% FCS (Fetal Calf Serum.
  • K562 (human myeloid) cells are cultured in RFMI medium supplemented with antibiotics and non-essential amino acids and containing 10 % FCS (0.5-1 x 10 6 cells/ml) . Both cell lines are cultured under a C0 2 atmosphere (37°C, 5% C0 2 ) .
  • the plasmid used is derived from the commercial plasmid pCMV5 into which the bacterial replication origin SI, the ampicillin resistance gene and the CAT gene of bacterial origin have been inserted. It is approximately 5000 base pairs in size and is stored at a concentration of 1 mg/ml .
  • the general procedure described above was fol ⁇ lowed; 5 ⁇ g (5 ⁇ l) of plasmid DNA and 11 ⁇ g (11 ⁇ l) of pure diC 14 -amidine suspension (or 25 ⁇ g (25 ⁇ l) of diC 14 - amidine/PE suspension) prepared as described above are used.
  • the CHO cells adhereent
  • the CHO cells are plated in the 6-well culture dishes the day before the experiment in an amount of 10 6 cells/well; while the K562 cells (in suspension) are used in an amount of 10 6 cells per experiment.
  • the incubation was carried out for 3 h for the two cell lines.
  • the transfection medium is the normal culture medium (with serum) with which vesicle vector (pure diC 14 -amidine or diC 14 -amidine/PE/DNA) has been mixed under the conditions described in the general procedure.
  • the cells are treated as described above; the CHO cells are transferred after 6 h into 100 mm culture dishes.
  • the two cell lines continue to grow for 36 h before the CAT assay performed as described by Gorman et al . , B.H. (1982) , Mol. Cell. Biol . 2, 1044-1051; in brief, the cell lysates are incubated at 37°C with [ 14 C] chloramphenicol and acetyl CoA for 2 h and extracted with ethyl acetate.
  • the organic phase is eluted by TLC (thin-layer chromatography) with chloroform/ methanol 95:5.
  • the cell lines of this example are CHO cells (adherent cells) and K562 cells (suspension cells) .
  • composition of the vector comprises: ⁇ g quantities of plasmid DNA and ⁇ g quantities of cationic vesicles.
  • the diC 14 allows transfection efficiencies with quantities two to three times lower than the available commercial products, namely DOTAP ® from Boehringer Mannheim and Lipofectin ® from Gibco BRL; in addition, the transfection efficiency advantageously limits the cyto- toxicity of the product used.
  • Example III Transfection of genetic material
  • BLV Bovine Leukemia Virus

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Plant Pathology (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Dispersion Chemistry (AREA)
  • Cell Biology (AREA)
  • Cosmetics (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Composé pouvant introduire au moins une molécule dans une cellule et répondant à la formule (I), dans laquelle A est sélectionné dans le groupe constitué des radicaux comportant un groupe hydrophile ou un groupe CH2 et un groupe hydrophobe; n est un entier positif; et R?2, R3 et R4¿ sont sélectionnés dans le groupe constitué d'un atome d'hydrogène, de chaînes alkyles saturées ou insaturées, et de chaînes alkyles substituées. On a également prévu une vésicule à charge positive dont la membrane comporte ce composé, un vecteur comportant au moins une molécule combinée avec cette vésicule, une cellule, un animal et/ou une plante transformé(e) par ledit composé ou ledit vecteur, et une composition pharmaceutique ou cosmétique comportant ledit vecteur et/ou la cellule transformée par ledit vecteur. En outre, on a prévu un procédé de synthèse dudit composé et un procédé de production dudit vecteur.
PCT/BE1994/000096 1993-12-20 1994-12-19 Compose pouvant introduire au moins une molecule dans une cellule WO1995017378A1 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
JP7517056A JPH09508099A (ja) 1993-12-20 1994-12-19 細胞中に少なくとも一つの分子を導入できる化合物
DE69430321T DE69430321T2 (de) 1993-12-20 1994-12-19 Verbindung geeignet zur einführung von wenigstens einem molekül in eine zelle
EP95902010A EP0736002B9 (fr) 1993-12-20 1994-12-19 Compose pouvant introduire au moins une molecule dans une cellule
AU11039/95A AU1103995A (en) 1993-12-20 1994-12-19 Compound capable of introducing at least one molecule into a cell

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17012493A 1993-12-20 1993-12-20
US08/170,124 1993-12-20

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US17012493A Continuation-In-Part 1993-12-20 1993-12-20

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US09/150,976 Continuation-In-Part US6613351B1 (en) 1993-12-20 1998-09-11 Compound capable of introducing at least one molecule into a cell

Publications (1)

Publication Number Publication Date
WO1995017378A1 true WO1995017378A1 (fr) 1995-06-29

Family

ID=22618638

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/BE1994/000096 WO1995017378A1 (fr) 1993-12-20 1994-12-19 Compose pouvant introduire au moins une molecule dans une cellule

Country Status (7)

Country Link
EP (1) EP0736002B9 (fr)
JP (1) JPH09508099A (fr)
AU (1) AU1103995A (fr)
CA (1) CA2179385A1 (fr)
DE (1) DE69430321T2 (fr)
ES (1) ES2173944T3 (fr)
WO (1) WO1995017378A1 (fr)

Cited By (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5650096A (en) * 1994-12-09 1997-07-22 Genzyme Corporation Cationic amphiphiles for intracellular delivery of therapeutic molecules
FR2745569A1 (fr) * 1996-03-01 1997-09-05 Centre Nat Rech Scient Composes apparentes a la famille des amidiniums, compositions pharmaceutiques les contenant et leurs applications
US5719131A (en) * 1994-12-09 1998-02-17 Genzyme Corporation Cationic amphiphiles containing dialkylamine lipophilic groups for intracellular delivery of therapeutic molecules
US5747471A (en) * 1994-12-09 1998-05-05 Genzyme Corporation Cationic amphiphiles containing steroid lipophilic groups for intracellular delivery of therapeutic molecules
US5767099A (en) * 1994-12-09 1998-06-16 Genzyme Corporation Cationic amphiphiles containing amino acid or dervatized amino acid groups for intracellular delivery of therapeutic molecules
US5783565A (en) * 1994-12-09 1998-07-21 Genzyme Corporation Cationic amphiphiles containing spermine or spermidine cationic group for intracellular delivery of therapeutic molecules
EP0902090A1 (fr) * 1997-09-12 1999-03-17 Universite Libre De Bruxelles Composé capable d'introduire au moins un molécule dans une cellule
US5910487A (en) * 1994-12-09 1999-06-08 Genzyme Corporation Cationic amphiphiles and plasmids for intracellular delivery of therapeutic molecules
US5912239A (en) * 1997-04-04 1999-06-15 Genzyme Corporation Imidazole-containing cationic amphiphiles for intracellular delivery of therapeutic molecules
US5925628A (en) * 1997-03-31 1999-07-20 Genzyme Corporation Cationic amphiphiles for intracellular delivery of therapeutic molecules
US5935936A (en) * 1996-06-03 1999-08-10 Genzyme Corporation Compositions comprising cationic amphiphiles and co-lipids for intracellular delivery of therapeutic molecules
US5942634A (en) * 1997-05-09 1999-08-24 Genzyme Corporation Cationic amphiphiles for cell transfections
US5948925A (en) * 1997-05-06 1999-09-07 Genzyme Corporation Cationic amphiphiles containing linkers derived from neutral or positively charged amino acids
US5948767A (en) * 1994-12-09 1999-09-07 Genzyme Corporation Cationic amphiphile/DNA complexes
US5952516A (en) * 1997-05-08 1999-09-14 Genzyme Corporation Cationic amphiphiles containing multiplesteroid lipophilic groups
US6331524B1 (en) 1994-12-09 2001-12-18 Genzyme Corporation Organ-specific targeting of cationic amphiphile / DNA complexes for gene therapy
US6383814B1 (en) 1994-12-09 2002-05-07 Genzyme Corporation Cationic amphiphiles for intracellular delivery of therapeutic molecules

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991015501A1 (fr) * 1990-04-04 1991-10-17 Yale University Introduction d'acide nucleique dans des cellules d'origine animale

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991015501A1 (fr) * 1990-04-04 1991-10-17 Yale University Introduction d'acide nucleique dans des cellules d'origine animale

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
ARM. KHIM. ZH., vol. 34, no. 5, 1981, MOSCOW, pages 370 - 374 *
ARNOLD J. GUTIERREZ ET AL, THE JOURNAL OF ORGANIC CHEMISTRY, vol. 54, no. 18, 1 September 1989 (1989-09-01), pages 4335 - 4344 *
CHEMICAL ABSTRACTS, vol. 95, no. 17, 26 October 1981, Columbus, Ohio, US; abstract no. 149705c, page 580; column L; *
FABIENNE DEFRISE-QUERTAIN ET AL, JOURNAL OF THE CHEMICAL SOCIETY. CHEMICAL COMMUNICATIONS, no. 13, 1 July 1986 (1986-07-01), pages 1060 - 1062 *
JEAN-MARIE RUYSSCHAERT ET AL, BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 203, no. 3, 30 September 1994 (1994-09-30), pages 1622 - 1628 *
K.J. SHEA ET AL, TETRAHEDRON LETTERS, vol. 27, no. 40, 1986, pages 4837 - 4840 *

Cited By (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5910487A (en) * 1994-12-09 1999-06-08 Genzyme Corporation Cationic amphiphiles and plasmids for intracellular delivery of therapeutic molecules
US5719131A (en) * 1994-12-09 1998-02-17 Genzyme Corporation Cationic amphiphiles containing dialkylamine lipophilic groups for intracellular delivery of therapeutic molecules
US5650096A (en) * 1994-12-09 1997-07-22 Genzyme Corporation Cationic amphiphiles for intracellular delivery of therapeutic molecules
US6331524B1 (en) 1994-12-09 2001-12-18 Genzyme Corporation Organ-specific targeting of cationic amphiphile / DNA complexes for gene therapy
US5767099A (en) * 1994-12-09 1998-06-16 Genzyme Corporation Cationic amphiphiles containing amino acid or dervatized amino acid groups for intracellular delivery of therapeutic molecules
US5783565A (en) * 1994-12-09 1998-07-21 Genzyme Corporation Cationic amphiphiles containing spermine or spermidine cationic group for intracellular delivery of therapeutic molecules
US5840710A (en) * 1994-12-09 1998-11-24 Genzyme Corporation Cationic amphiphiles containing ester or ether-linked lipophilic groups for intracellular delivery of therapeutic molecules
US5948767A (en) * 1994-12-09 1999-09-07 Genzyme Corporation Cationic amphiphile/DNA complexes
US6383814B1 (en) 1994-12-09 2002-05-07 Genzyme Corporation Cationic amphiphiles for intracellular delivery of therapeutic molecules
US5747471A (en) * 1994-12-09 1998-05-05 Genzyme Corporation Cationic amphiphiles containing steroid lipophilic groups for intracellular delivery of therapeutic molecules
FR2745569A1 (fr) * 1996-03-01 1997-09-05 Centre Nat Rech Scient Composes apparentes a la famille des amidiniums, compositions pharmaceutiques les contenant et leurs applications
US5935936A (en) * 1996-06-03 1999-08-10 Genzyme Corporation Compositions comprising cationic amphiphiles and co-lipids for intracellular delivery of therapeutic molecules
US5925628A (en) * 1997-03-31 1999-07-20 Genzyme Corporation Cationic amphiphiles for intracellular delivery of therapeutic molecules
US5912239A (en) * 1997-04-04 1999-06-15 Genzyme Corporation Imidazole-containing cationic amphiphiles for intracellular delivery of therapeutic molecules
US5948925A (en) * 1997-05-06 1999-09-07 Genzyme Corporation Cationic amphiphiles containing linkers derived from neutral or positively charged amino acids
US5952516A (en) * 1997-05-08 1999-09-14 Genzyme Corporation Cationic amphiphiles containing multiplesteroid lipophilic groups
US5942634A (en) * 1997-05-09 1999-08-24 Genzyme Corporation Cationic amphiphiles for cell transfections
EP0902090A1 (fr) * 1997-09-12 1999-03-17 Universite Libre De Bruxelles Composé capable d'introduire au moins un molécule dans une cellule

Also Published As

Publication number Publication date
AU1103995A (en) 1995-07-10
EP0736002A1 (fr) 1996-10-09
EP0736002B9 (fr) 2002-12-18
DE69430321D1 (de) 2002-05-08
EP0736002B1 (fr) 2002-04-03
CA2179385A1 (fr) 1995-06-29
ES2173944T3 (es) 2002-11-01
DE69430321T2 (de) 2003-09-25
JPH09508099A (ja) 1997-08-19

Similar Documents

Publication Publication Date Title
EP0736002B9 (fr) Compose pouvant introduire au moins une molecule dans une cellule
KR101773643B1 (ko) 양이온성 지질
US6020526A (en) Amide-based cationic lipids
US9668973B2 (en) Components for producing amphoteric liposomes
US6034135A (en) Dimeric cationic lipids
US6716882B2 (en) Highly packed polycationic ammonium, sulfonium and phosphonium lipids
TWI594767B (zh) 含有陽離子性脂質之藥物傳遞系統用脂質奈米粒子
US5877220A (en) Amide-based oligomeric cationic lipids
KR19990067552A (ko) 형질감염제로서의 리포폴리아민 및 이의 약학적 용도
US6346516B1 (en) Cationic amphiphiles containing N-hydroxyalkyl group for intracellular delivery of biologically active molecules
EP3301086A1 (fr) Lipide cationique
CA3200768A1 (fr) Complexes anticorps-oligonucleotide et utilisations associees
KR20170012366A (ko) CKAP5 유전자 발현 억제 RNAi 의약 조성물
CN116472275A (zh) 脂质化合物和脂质纳米颗粒组合物
US6613351B1 (en) Compound capable of introducing at least one molecule into a cell
EP3888663A1 (fr) Complexe d'acide nucléique
JP2019024444A (ja) 核酸複合体
CN116675624A (zh) 一种脂质化合物及脂质纳米颗粒
WO2022235935A2 (fr) Lipides cationiques ionisables d'administration d'arn
EP1300161A1 (fr) Lipides cationiques pour le transfert de gènes
JPH03147793A (ja) 合成２分子膜を用いた核酸の細胞内導入の方法

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AM AU BB BG BR BY CA CN CZ EE FI GE HU JP KE KG KP KR KZ LK LR LT LV MD MG MN MW NO NZ PL RO RU SD SI SK TJ TT UA US UZ VN

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): KE MW SD SZ AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref document number: 1996 663294

Country of ref document: US

Date of ref document: 19960303

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2179385

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 1995902010

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1995902010

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 1995902010

Country of ref document: EP